
US-based Synthekine engineers cytokines to develop transformative treatments for cancer and autoimmune disorders.
Founded in Menlo Park, United States, Synthekine is dedicated to developing disease-optimized treatments through engineered cytokine therapeutics. The company's core mission is to harness immunological insights to guide targeted protein engineering, creating transformative medicines for cancer and autoimmune disorders. Synthekine focuses on discovering, developing, and commercializing the next generation of selective cytokine therapeutics to address unmet medical needs in these markets.
Synthekine has attracted notable investors and affiliations with leading experts in immunology and biotechnology. The company has achieved significant milestones, including advancing its proprietary cytokine engineering platform and initiating clinical trials for its lead candidates. Synthekine's innovative approach has the potential to significantly impact the treatment landscape for cancer and autoimmune diseases, offering new hope for patients with these challenging conditions.

Kyverna Therapeutics

Deka Biosciences

Simcha Therapeutics
simchatx.com

ImmunGene

AskGene Pharma

MacroGenics
macrogenics.com

Synkrino Biotherapeutics
synkrino.bio

Eikon Therapeutics
eikontx.com

Celsius Therapeutics
celsiustx.com

HI-Bio
hibio.com

Cel-Sci
cel-sci.com

Siren Biotechnology

Cue Biopharma

Ernexa Therapeutics
eternatx.com

Synedgen
synedgen.com
Companies similar to Synthekine include Kyverna Therapeutics, Deka Biosciences, Simcha Therapeutics and ImmunGene.
Synthekine was founded in 2018.
Synthekine's headquarters is located in Menlo Park, CA, US.
Synthekine's most recent funding round was for $100M (USD) in January 2023.
As of Jan 6, 2023, Synthekine has raised a total of $289.5M (USD).
Synthekine has 122 employees as of Feb 4, 2024.